The 11 hottest jobs on Wall Street in 2015 (eFinancialCareers)

Water Cooler Careers
#1

http://news.efinancialcareers.com/us-en/204154/the-11-hottest-jobs-on-wall-street-in-2015 “…banks really are recruiting, just not in the areas you might expect. These are the most sought-after skills on Wall Street this year.” 1. Junior M&A and leveraged finance bankers 2. Healthcare investment bankers 3. Post-MBA private equity professionals 4. Compliance analysts 5. Business analysts and project managers for regulatory change initiatives 6. Financial advisors with sticky clients 7. Structured products analysts 8. Tech-focused venture capitalists 9. Top deal-makers willing to help lower-ranked investment banks 10. Internal auditors 11. Data scientists

#2

#1 won’t stay number 1 for that long if yields go up

#2 will still stay hot though, HC M&A is likely to remain searing hot

#3

Internal auditors making it rain! No love for CRE?

#4

@itera what makes you say #2 “will stay hot”.

Biotech in particular is driving up healthcare and historically its pretty cyclical/there would appear at first glance to be a “patent cliff”. See link below:

http://www.dailywealth.com/1722/biotech-stocks-overdue-bull-run

I’m not trying to tell you you’re wrong here in any way, but I’m curious why you’re so confident about that call man.

#5

Biotech has been #1 best performer for 4 years now. The biotech boom is still going on now with new IPO/secondaries. Even if this slows down, there’s still plenty of companies to continue fueling the huge M&A acquisition spree the big players are going to have over the next 3-4 years.

Funds are falling over themselves trying to get analysts that know the therapeutic spaces (biotech, pharma…etc), and HC bankers are in huge demand.

#6

I would see #4 and #11 continuing to be hot

#7

Last year I worked shortly for an IB boutique that could only get its hands on the most speculative/shittiest deals. One of their clients was a biotech firm (product-development phase in DNA sequencing).

To this day, I am convinced that nobody I ever spoke with understood wtf it is they were doing. From our analysts to the people who bought their equity.

I remember even making a thread here about whether it made sense to read up on that field to understand it. Anyways I decided to NGAF and quit that job.

So yeah, I agree with the bolded statement, it is extremely specialised and from what I have seen, the analysis of development phase biotech stocks has little to do conventional stock valuation.